Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval on MAH therapy in the U.S. This conversation covers the larger, downstream changes we will see in how MASLD and MASH are treated in the U.S.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
Hannes Hagstrom and the Surfers consider the ways that increased access to in-office screening will affect clinical care pathways, with special focus on the role of primary care practices.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?
